Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
Archive, CME credit no longer available
Release Date: July 1, 2007
Expiration Date: July 1, 2008
The live meeting, held from June 14 to 16, 2007, and this webcast are planned with and supported by the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, and produced in collaboration with the Southeast AIDS Training and Education Center (SEATEC).
This activity consists of audio and visual recording of 17 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Identify current issues and future trends in the HIV epidemic and the populations impacted
- Discuss new recommendations in HIV testing and their potential impact on medical practice and healthcare system
- Design antiretroviral treatment regimens that consider:
- Current information on initiating antiretroviral therapy
- Management of complicated antiretroviral failure and drug resistance
- The role of HIV resistance testing and nuances in interpretation of the results
- The status of new investigational antiretrovirals and new drug classes
- Long-term metabolic complications, including insulin resistance and bone disorders
- Develop counseling strategies to address the relationship between HIV and domestic violence
- Discuss current treatment strategies for HIV-infected patients with coexisting conditions such as substance use, chronic pain, and mental health disorders
- Describe the incidence, diagnosis, and management of specific coinfections commonly seen in HIV-infected patients, including hepatitis B and C viruses
Intended Audience for CME Credit
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Co-Chairs
Laura W. Cheever, MD
Chief Medical Officer
Deputy Associate Administrator
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
J. Kevin Carmichael, MD
Chief of Service
El Rio Special Immunology Associates
Tucson, Arizona
Michael S. Saag, MD
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Director, Division of Infectious Diseases
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Program Planning Committee
Laura W. Cheever, MD
Chief Medical Officer
Deputy Associate Administrator
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Donna M. Jacobsen
President and Founding Executive Director
International AIDS Society–USA
San Francisco, California
J. Kevin Carmichael, MD
Chief of Service
El Rio Special Immunology Associates
Tucson, Arizona
José R. Morales, MD
Director
Division of Community Based Programs
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Michael S. Saag, MD
Volunteer Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Director, Division of Infectious Diseases
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Dianne H. Weyer, NP
Senior Clinical Instructor
Southeast AIDS Training and Education Center
Atlanta, Georgia
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)
Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)
Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)
Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)
Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)
Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)
Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)
Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Angelino had no relevant financial affiliations to disclose.
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex.
Dr Cheever had no relevant financial affiliations to disclose.
Dr Dieterich received grant and research support or honoraria from Gilead, GlaxoSmithKline, Roche, and Schering. He served as a consultant or was on the speakers’ bureaus of Gilead, GlaxoSmithKline, Roche, and Schering.
Dr Fenton had no relevant financial affiliations to disclose.
Dr Fullilove had no relevant financial affiliations to disclose.
Dr Gallant received grants and research support from Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, and Roche. He served as a scientific advisor or consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Tibotec, and Monogram Sciences.
Dr Grunfeld received grants and research support from Merck, Serono, and Thera Technologies. He received honoraria from Abbott and Bristol-Myers Squibb.
Dr Khalsa had received grants and research support from Abbott, GlaxoSmithKline, Merck, Pfizer, and Tibotec. She served as a consultant or scientific advisor to and was on the speakers’ bureaus of Abbott and GlaxoSmithKline. She received fees for written enduring materials, Internet activities and/or audio activities or honoraria for speaking from Abbott, Bristol-Myers Squibb, and GlaxoSmithKline.
Dr Morales had no relevant financial information to disclose.
Dr O’Connor had no relevant financial affiliations to disclose.
Dr Ross was on the speakers’ bureau of Gilead Sciences.
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex.
Dr Scott was on the speakers’ bureaus of Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, and GlaxoSmithKline.
Dr Smith served as a scientific advisor to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Tanox, Tibotec/Virco, and Vertex.
Dr Sweet had no relevant financial affiliations to disclose.
Dr Tebas received grants and research support from Bristol-Myers Squibb, Pfizer, Roche, Tibotec, VGX, and VIRxSYS. He served as a consultant to Bristol-Myers Squibb, Merck, Pfizer, Tibotec, and VGX.
Dr Treisman was on the speakers’ bureaus of Boehringer Ingelheim and Pfizer.
Dr Thornton had no relevant financial affiliations to disclose.
Ms Weyer was on the speakers’ bureau of Boehringer Ingelheim.
Dr Wilkin served as a consultant to Abbott and Gilead. He was on the speakers’ bureau of GlaxoSmithKline.
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, the AIDS Education and Training Centers National Resource Center, and the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2007@iasusa.org
